Objective: To evaluate the histomorphology of skin and its appendages, especially eccrine sweat glands, in patients with GH disorders, because reduced sweating ability in patients with growth hormone de®ciency (GHD) is associated with increased risk of hyperthermia under stressed conditions. Design and methods: A skin biopsy was obtained from 17 patients with GHD treated with GH, ®ve patients with untreated GHD, 10 patients with active acromegaly and 13 healthy controls. Results: The sweat secretion rate (SSR) was signi®cantly decreased in both the untreated (median 41 mg/30 min, range 9±79 mg/30 min) and the GH-treated (median 98 mg/30 min, range 28± 147 mg/30 min) patients with GHD compared with that in controls (median 119 mg/30 min, range 90±189 mg/30 min; P 0X001 and 0.01 respectively). Epidermal thickness was signi®cantly decreased in both untreated (median 39 mm, range 28±55 mm) and GH-treated patients with GHD (median 53 mm, range 37±100 mm), compared with that in controls (median 66 mm, range 40± 111 mm; P , 0X02X A statistically non-signi®cant tendency towards thinner epidermis (median 59 mm, range 33±83 mm) was recorded in acromegalic patients P 0X08 compared with controls. There was no signi®cant difference in the area of the sebaceous glands in the biopsies between the three groups and the controls. The area of eccrine sweat gland glomeruli was signi®cantly decreased in the untreated patients with GHD (median 16407 mm 2 , range 12758±43976 mm 2 ) compared with that in controls (median 29446 mm 2 , range 13511±128661 mm 2 ; P 0X03Y but there was no signi®cant difference between the GH-treated patients with GHD and controls. Conclusions: We conclude that GH, either directly or via IGF-I, may have both a structural and a functional effect on human skin and its appendages, and that patients with GHD have histomorphological changes in skin compared with controls. Importantly, these changes are not fully reversed despite long-term and adequate GH treatment in patients with childhood onset GHD.